Novavax
NVAX
$4.09
Share price
3.54%
Change (1 day)
-46.68%
Change (1 year)
Categories
Novavax (NVAX) - Total debt
Total debt on the balance sheet as of December 2023 : $0.22 B
According to Novavax's latest financial reports the company's total debt is $0.22 B. A company’s total debt is the sum of all current and non-current debts.
Novavax - Total debt on balance sheet (from 2001 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $0.22 B | -58.33% |
| 2022-12-31 | $0.54 B | 21.1% |
| 2021-12-31 | $0.45 B | -2.99% |
| 2020-12-31 | $0.46 B | 45.39% |
| 2019-12-31 | $0.32 B | 0.84% |
| 2018-12-31 | $0.31 B | 0.45% |
| 2017-12-31 | $0.31 B | 0.45% |
| 2016-12-31 | $0.31 B | 79985.82% |
| 2015-12-31 | $0.39 M | -60.42% |
| 2014-12-31 | $0.99 M | -46.94% |
| 2013-12-31 | $1.88 M | 56.1% |
| 2012-12-31 | $1.2 M | 276.56% |
| 2011-12-31 | $0.32 M | -20% |
| 2010-12-31 | $0.4 M | -17.7% |
| 2009-12-31 | $0.48 M | -97.88% |
| 2008-12-31 | $22.9 M | 0.7% |
| 2007-12-31 | $22.74 M | -1.9% |
| 2006-12-31 | $23.18 M | -24.05% |
| 2005-12-31 | $30.53 M | -17.85% |
| 2004-12-31 | $37.16 M | -11.86% |
| 2003-12-31 | $42.16 M | 1.84% |
| 2002-12-31 | $41.4 M | 20.58% |
| 2001-12-31 | $34.33 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $27.28 B | 11,810.20% | 🇨🇭 Switzerland |
 Pfizer PFE | $70.84 B | 30,825.74% | 🇺🇸 USA |
 AstraZeneca AZN | $34.55 B | 14,982.44% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $22.93 B | 9,912.57% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | $1.39 B | 509.75% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | $2.54 M | -98.89% | 🇺🇸 USA |
 Agenus
AGEN | $78.01 M | -65.95% | 🇺🇸 USA |
 NanoViricides NNVC | $1.5 M | -99.35% | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | $0.82 B | 260.20% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | $0.86 B | 275.50% | 🇺🇸 USA |